Chemotherapy for Triple-Negative Breast Cancer: Is More Better?
Author:
Affiliation:
1. Dana-Farber Cancer Institute, Brigham & Women’s Hospital, and Harvard Medical School, Boston, MA
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2016.68.4068
Reference15 articles.
1. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
2. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
3. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
4. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer
5. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Exploiting a tumor softening targeted bomb for mechanical gene therapy of chemoresistant Triple-Negative breast cancer;Chemical Engineering Journal;2024-10
2. A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer;Proceedings of the National Academy of Sciences;2024-01-17
3. Exploiting a Tumor Softening Targeted Bomb for Mechanical Gene Therapy of Chemoresistant Triple-Negative Breast Cancer;2024
4. Inhibition of ERK signaling for treatment of ERRα positive TNBC;PLOS ONE;2023-05-10
5. Antiproliferative Effect of Inorganic and Organic Selenium Compounds in Breast Cell Lines;Biomedicines;2023-05-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3